Cidara Therapeutics, Inc. financial data

Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 607% % 204%
Quick Ratio 8.2% %
Debt-to-equity 19% % -82%
Return On Equity -60% % 73%
Return On Assets -51% % 52%
Operating Margin -63851% % -3179%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31,439,371 shares 346%
Common Stock, Shares, Outstanding 29,335,397 shares 316%
Entity Public Float $53,300,000 USD -47%
Common Stock, Value, Issued $3,000 USD 200%
Weighted Average Number of Shares Outstanding, Basic 26,882,366 shares 312%
Weighted Average Number of Shares Outstanding, Diluted 26,882,366 shares 312%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Revenue from Contract with Customer, Excluding Assessed Tax $2,826,000 USD
Research and Development Expense $131,820,000 USD 453%
Operating Income (Loss) $195,463,000 USD -39%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $15,535,000 USD -303%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $184,738,000 USD -53%
Earnings Per Share, Basic -8 USD/shares 67%
Earnings Per Share, Diluted -8 USD/shares 67%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $293,651,000 USD 131%
Accounts Receivable, after Allowance for Credit Loss, Current $1,861,000 USD 9.5%
Inventory, Net $7,269,000 USD
Assets, Current $442,821,000 USD 182%
Property, Plant and Equipment, Net $293,000 USD -48%
Operating Lease, Right-of-Use Asset $1,795,000 USD -41%
Other Assets, Noncurrent $23,582,000 USD 1799%
Assets $518,650,000 USD 220%
Accounts Payable, Current $4,351,000 USD 47%
Employee-related Liabilities, Current $3,506,000 USD -29%
Accrued Liabilities, Current $71,349,000 USD 733%
Liabilities, Current $95,839,000 USD 116%
Operating Lease, Liability, Noncurrent $424,000 USD -79%
Liabilities $96,263,000 USD 106%
Accumulated Other Comprehensive Income (Loss), Net of Tax $107,000 USD
Retained Earnings (Accumulated Deficit) $743,689,000 USD -33%
Stockholders' Equity Attributable to Parent $422,387,000 USD 265%
Liabilities and Equity $518,650,000 USD 220%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $21,950,000 USD -230%
Net Cash Provided by (Used in) Financing Activities $77,000 USD
Net Cash Provided by (Used in) Investing Activities $185,000 USD
Common Stock, Shares Authorized 100,000,000 shares 100%
Common Stock, Shares, Issued 29,335,397 shares 316%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $21,688,000 USD -221%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $299,988,000 USD 135%
Deferred Tax Assets, Valuation Allowance $120,898,000 USD 46%
Deferred Tax Assets, Gross $121,680,000 USD 44%
Operating Lease, Liability $1,984,000 USD -40%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $184,845,000 USD -53%
Lessee, Operating Lease, Liability, to be Paid $2,147,000 USD -43%
Property, Plant and Equipment, Gross $3,865,000 USD 3.1%
Operating Lease, Liability, Current $1,560,000 USD 18%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,731,000 USD 4%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,731,000 USD 4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $163,000 USD -67%
Deferred Tax Assets, Operating Loss Carryforwards $46,721,000 USD 32%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $12,906,000 USD 12%
Operating Lease, Payments $400,000 USD 0%
Deferred Tax Assets, Net of Valuation Allowance $782,000 USD -48%
Share-based Payment Arrangement, Expense $9,525,000 USD 209%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%